Wall Street Zen Downgrades GH Research (NASDAQ:GHRS) to Sell

Wall Street Zen lowered shares of GH Research (NASDAQ:GHRS) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.

A number of other brokerages have also recently issued reports on GHRS. Cantor Fitzgerald upgraded GH Research to a “strong-buy” rating in a report on Tuesday, May 13th. Royal Bank of Canada began coverage on GH Research in a report on Friday, March 7th. They set an “outperform” rating and a $31.00 target price for the company. Guggenheim decreased their target price on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a report on Friday, May 9th. Stifel Nicolaus boosted their target price on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.43.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $11.17 on Thursday. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50. The stock has a market capitalization of $581.15 million, a P/E ratio of -14.14 and a beta of 0.86. The stock has a 50-day simple moving average of $10.36 and a 200-day simple moving average of $10.06.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.42. Analysts predict that GH Research will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. boosted its holdings in GH Research by 3.9% in the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after acquiring an additional 257,959 shares during the period. Lynx1 Capital Management LP boosted its holdings in GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after acquiring an additional 663,100 shares during the period. Cormorant Asset Management LP boosted its stake in shares of GH Research by 238.8% during the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company’s stock valued at $22,165,000 after buying an additional 1,416,439 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of GH Research during the 1st quarter valued at approximately $8,272,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of GH Research during the 1st quarter valued at approximately $5,018,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).